Xencor, Inc. (NASDAQ:XNCR) – Investment analysts at Wedbush raised their FY2017 earnings estimates for Xencor in a research note issued to investors on Monday. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($0.85) for the year, up from their prior estimate of ($1.06). Wedbush also issued estimates for Xencor’s Q4 2017 earnings at ($0.06) EPS, FY2019 earnings at ($1.92) EPS, FY2020 earnings at ($0.47) EPS and FY2021 earnings at ($2.22) EPS.
A number of other brokerages have also issued reports on XNCR. Cantor Fitzgerald initiated coverage on shares of Xencor in a research note on Wednesday, November 29th. They issued an “overweight” rating and a $33.00 target price on the stock. ValuEngine lowered shares of Xencor from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. BidaskClub upgraded shares of Xencor from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 7th. Zacks Investment Research upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Finally, Canaccord Genuity set a $36.00 target price on shares of Xencor and gave the company a “buy” rating in a research note on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $30.80.
In other Xencor news, major shareholder John S. Stafford III acquired 50,000 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The shares were purchased at an average price of $19.58 per share, for a total transaction of $979,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder John S. Stafford III acquired 150,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The shares were acquired at an average price of $19.81 per share, for a total transaction of $2,971,500.00. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 278,535 shares of company stock worth $5,526,936. 4.03% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can raised its stake in Xencor by 158.9% during the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 4,005 shares during the period. SG Americas Securities LLC raised its stake in Xencor by 62.6% during the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock worth $178,000 after acquiring an additional 3,252 shares during the period. Principal Financial Group Inc. acquired a new stake in shares of Xencor in the third quarter valued at approximately $201,000. Legal & General Group Plc increased its stake in shares of Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 385 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in shares of Xencor in the second quarter valued at approximately $224,000. Hedge funds and other institutional investors own 77.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.com-unik.info/2017/12/22/brokers-issue-forecasts-for-xencor-inc-s-fy2017-earnings-xncr.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.